The Oregon Health Authority has withdrawn its proposal to double licensing fees for psilocybin service providers, marking a rare reversal after coordinated industry resistance.
OHA notified stakeholders Tuesday that the agency would no longer pursue the fee increases through its current rulemaking process. The proposed changes would have raised costs across multiple license categories in Oregon's regulated psilocybin program, which launched in 2023 as the first of its kind in the United States.
"OHA dropping this rulemaking is a win, but it does not mean we've won," said Jack Gorsline of Psychedelic State(s) of America, suggesting continued vigilance from industry advocates.
The Proposed Fee Structure
The withdrawn rules would have effectively doubled licensing costs for manufacturers, service centers, and facilitators operating in Oregon's psilocybin space. Industry groups argued the increases would burden businesses already struggling with high operational costs and limited client volume in the nascent market.
Oregon's psilocybin program operates under Measure 109, which voters approved in 2020. The system allows licensed facilitators to administer psilocybin in controlled settings for adults 21 and older, separate from the state's medical cannabis program.
Since launching commercial operations, the program has faced challenges with client adoption and revenue generation. Higher licensing fees would have compounded financial pressures on service providers trying to establish viable business models in an untested market.
Industry Response
Stakeholders mobilized quickly against the fee proposal through public comment periods and direct advocacy with state officials. The pushback highlighted tensions between OHA's need to fund program oversight and industry concerns about affordability in a market still finding its footing.
The fee withdrawal comes as other states watch Oregon's psilocybin experiment closely. Colorado voters approved a similar measure in 2022, and regulators there are developing their own licensing framework. How Oregon handles operational costs and fee structures could influence approaches in other jurisdictions.
What's Next
While OHA has dropped this specific rulemaking, the agency has not ruled out future fee adjustments. Program funding remains an open question as the state works to balance regulatory costs with industry sustainability.
The psilocybin sector continues to operate in a legal gray area federally, with psychedelic compounds still classified as Schedule I substances. That creates banking and interstate commerce challenges similar to those faced by cannabis operators, though the psilocybin industry is smaller and less established.
Industry advocates say they'll continue monitoring OHA's regulatory approach and engaging with policymakers on program development. The fee withdrawal suggests state officials are listening to operator concerns, but long-term funding solutions for program oversight remain unresolved.
This article is based on original reporting by www.marijuanamoment.net.
